KLHL29 activators constitute a novel chemical class designed to specifically enhance the activity of the Kelch-like family member 29 (KLHL29) protein. This group of chemicals operates by promoting the functional engagement of KLHL29 with its substrates, thereby facilitating ubiquitin ligase activity which is crucial for the ubiquitination and subsequent proteasomal degradation of target proteins. Activation of KLHL29 can influence a wide array of cellular functions, including but not limited to, cell cycle progression, signal transduction pathways, and the maintenance of cellular homeostasis. The discovery and development of KLHL29 activators are grounded in the intricate understanding of the protein's structure and operational mechanisms. Techniques such as high-throughput screening, alongside computational biology and molecular docking studies, play pivotal roles in identifying potential activator compounds. These methods allow for the mapping of active sites and the assessment of molecular interactions between KLHL29 and candidate activators, ensuring the selection of compounds with optimal binding affinity and specificity.
Upon identification, KLHL29 activators undergo rigorous optimization processes to enhance their efficacy, selectivity, and pharmacokinetic profiles. This optimization is informed by detailed structure-activity relationship (SAR) analysis, which elucidates how modifications to the chemical structure of the activators impact their biological activity. Additionally, cellular assays are employed to confirm the ability of these compounds to increase KLHL29-mediated ubiquitination levels, further validating their mode of action within biological systems. Instead, the primary aim lies in understanding how modulation of KLHL29 activity by these activators affects cellular processes and pathophysiological states. This approach not only contributes valuable insights into the ubiquitin-proteasome system's functioning but also highlights the potential of KLHL29 activators as tools for further research into the mechanisms governing protein degradation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG can influence various cellular signaling pathways, potentially impacting KLHL29-related processes. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin affects multiple cellular pathways and may indirectly modulate KLHL29 function. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Known for its role in modulating various signaling pathways, which might indirectly influence KLHL29. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium affects Wnt signaling and other pathways, potentially impacting KLHL29's activity. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, potentially affecting pathways related to KLHL29. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can influence various cellular processes, possibly affecting KLHL29. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
By inhibiting MEK, this compound could affect pathways involving KLHL29. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Inhibiting p38 MAPK may impact signaling pathways relevant to KLHL29's function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
By inhibiting PI3K, it may indirectly affect KLHL29 through various signaling pathways. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This DNA methyltransferase inhibitor could influence gene expression, potentially affecting KLHL29. | ||||||